ArticleFrontiers in immunology2026
The free fatty acid 2 receptor regulates C5a induced neutrophil superoxide production and its sensitivity to inhibition by the antagonist avacopan.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Receptor transactivation is a novel signaling mechanism used by several different neutrophil G protein-coupled receptors (GPCRs) to activate an allosterically modulated receptor that recognizes short chain free fatty acids. The C5a receptor recognizes the complement-derived chemoattractant C5a, a potent activator of the neutrophil superoxide anion generating NADPH oxidase. The aim of the study was to investigate the ability for the C5a receptor to generate receptor transactivating signals. Methods: A rise in the cytosolic concentration of free calcium ions and activation of the NADPH oxidase were used as functional read-out systems. Results: An allosteric modulator (Cmp58) for the fatty acid receptor increased the activating potency but not the efficacy of C5a. The allosteric modulator also reduced the inhibitory effect of the C5a receptor antagonist avacopan, suggesting that the NADPH oxidase is activated by two different signaling pathways downstream of the C5a receptor. While the allosteric modulator affected the NADPH oxidase activity, the C5a-induced rise in the intracellular concentration of free calcium ions was unaffected. Activated C5a receptors thus generate signals that both directly activate the NADPH oxidase and transactivate free fatty acid receptors, which subsequently generate signals that elicit NADPH oxidase activity. In addition, the free fatty acid receptor was ranked higher than the receptor for C5a, in the neutrophil receptor hierarchy. Conclusions: The results are in line with an earlier described receptor transactivation model, in which the free fatty acid receptor is activated by signal signals generated by other neutrophil GPCRs to which we now add the C5a receptor. The dual receptor trans-regulatory effects, whereby the receptor for C5a activates the free fatty acid receptor and by which this receptor attenuates the C5a response, represent new regulatory mechanisms of importance for the NADPH oxidase activity in neutrophils.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.